REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

RGNX Income Before Tax

Profit after all operating and non-operating items but before income tax.

REGENXBIO Inc.NASDAQ: RGNX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax turns negative

Q1 FY2026 income before tax was -$90.05M, compared with $6.08M a year earlier. Trailing-twelve-month income before tax was -$290.01M.

Context

  • Income before tax amounted to 113.8% of revenue in FY2025, down 158.8 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$90.05M or moves back toward the trailing-twelve-month quarterly average of -$72.5M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$90.05M-34.1% QoQ
Last fiscal yearDec 2025
-$193.88M+14.6% YoY
LTMMar 2026
-$290.01M-83.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1580.4%——
1 year+14.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(193.88M) USD
Year-over-year change
+14.6%

Income Before Tax vs competitors

How RGNX compares with its peers on the latest reported figures

  • RGNX's LTM Mar 2026 income before tax of -$290.01M is the lowest of the 10 companies compared; the peer median is -$157.71M.
  • Its year-over-year change of -83.9% is the lowest of 10, against a peer median of +5.6%.
  • Income before tax amounts to 330.2% of revenue for RGNX, versus a peer median of 251.6%.
RGNX Competitors Peer median
Income Before Tax for RGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCGNOcugen, Inc.LTM Mar 2026-$71.67M -24.7%—1605.2%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$87.5M +19.9%——
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$116.52M -38.7%—319.3%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$120.53M +28.0%—151.1%
PGENPrecigen, Inc.LTM Jun 2026-$157.71M -26.6%—184.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$160.9M +8.8%—182.3%
SLDBSolid Biosciences Inc.LTM Mar 2026-$191.78M -37.3%——
QUREuniQure N.V.LTM Mar 2026-$203.25M +5.6%—1123.3%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$209.38M +18.9%——
RGNXREGENXBIO Inc.LTM Mar 2026-$290.01M -83.9%—330.2%
Peer median (excluding RGNX) -$157.71M+5.6%—251.6%

Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue470.35M112.72M90.24M83.33M170.44M
Cost of Revenue51.83M54.55M37.21M33.57M20.3M
Gross Profit418.51M58.18M53.03M49.76M150.14M
Gross Margin89.0%51.6%58.8%59.7%88.1%
Research & Development181.44M242.45M232.27M208.52M228.3M
Selling, General & Admin79.33M85.28M88.49M76.62M82.86M
Operating Expenses258.53M321.06M321.16M283.11M311.34M
Depreciation & Amortization9.56M12.91M17.32M16.22M15.62M
EBITDA177.09M(244.24M)(239.46M)(198.23M)(133.26M)
EBITDA Margin37.7%-216.7%-265.4%-237.9%-78.2%
Operating Income159.98M(262.88M)(268.13M)(233.35M)(161.2M)
Operating Margin34.0%-233.2%-297.1%-280.0%-94.6%
Interest Income719K342K25K174K12.27M
Interest Expense26.28M23.25M6.86M12.66M45.01M
Other Income / Expenses(18.73M)(17.53M)4.48M6.24M(32.68M)
Income Before Tax141.25M(280.41M)(263.65M)(227.1M)(193.88M)
Pre-Tax Margin30.0%-248.8%-292.2%-272.5%-113.8%
Income Tax Expense13.41M(84K)(152K)00
Net Income127.84M(280.32M)(263.49M)(227.1M)(193.88M)
Net Margin27.2%-248.7%-292.0%-272.5%-113.8%
EPS (Basic)3.01(6.50)(6.02)(4.59)(3.76)
EPS (Diluted)2.91(6.50)(6.02)(4.59)(3.76)
Weighted Avg Shares42.44M43.15M43.73M49.51M51.57M
Weighted Avg Shares (Diluted)43.91M43.15M43.73M49.51M51.57M

REGENXBIO Inc.

NASDAQ:RGNX

Intrinsic Alpha fair value

Locked

Current Price

$7.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.